20
Nov
Pfizer has launched its new Rimegepant orally disintegrating tablet (ODT) in India for the acute treatment of migraine, with or without aura, in adults who have previously shown insufficient response to triptans. Approved by the Drug Controller General of India (DCGI), the 75 mg ODT can be taken with or without food and dissolves without the need for water, offering convenience and rapid action. Pfizer said the medication provides quick and sustained pain relief for up to 48 hours and does not carry the risk of medication overuse headaches. By targeting the calcitonin gene-related peptide (CGRP), a key factor in…
